Respiratory Syncytial Virus (RSV) for Health Professionals
- Reporting Respiratory Syncytial Virus (RSV)
Reporting RSV to MDH.
- LTC Facility Influenza and RSV Report Form 2023-2024
MDH collects reports of outbreaks of RSV and influenza among residents living in long term care facilities. Please follow this link for more information and to fill out our online reporting form.
Infection prevention and control
- American Academy of Pediatrics Red Book: RSV
American Academy of Pediatrics (AAP) reference with information on clinical manifestations, epidemiology, infection prevention, and control measures.
- Hennepin County infectious diseases in childcare settings and schools manual
Section 6 contains fact sheets for school and child care providers on diseases including RSV. Information on signs and symptoms, spread, exclusion, and prevention and control.
Palivizumab (also known as Synagis), is a monoclonal antibody used to prevent severe disease in certain infants most at risk for hospitalization due to RSV. Providers are encouraged to follow the updated American Academy of Pediatrics (AAP) guidance on the use of palivizumab prophylaxis in eligible infants.
- AAP 2014 Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection
- AAP Updated Guidance: Use of Palivizumab Prophylaxis to Prevent Hospitalization From Severe Respiratory Syncytial Virus Infection During the 2022-2023 RSV Season
- CDC: Adult RSV ACIP Vaccine Recommendations
- Immunize.org: RSV Vaccine Information Statement (VIS)
- CDC: Healthcare Providers: RSV Vaccination for Adults 60 Years of Age and Over
- CDC: RSV for Healthcare Providers